Kartick Pramanik, PhD, M Pharm, B Pharm

Assistant Professor of Pharmacology

  • Office: Coal Building, 814
  • Telephone: (606) 218-5423
  • E-mail: kartickpramanik@upike.edu

Medical Pharmacology
Molecular Pharmacology

BS, Pharmacy, Jadavpur University
MS, Pharmacology, Jadavpur University
PhD, Pharmacology, Jadavpur University
Postdoctoral, Pharmacology, Texas Tech University and Penn State University

Kartick C. Pramanik, Monish Ram Makena, Kuntal Bhowmick and Manoj K. Pandey, Advancement of NF-κB Signaling Pathway: A Novel Target in Pancreatic Cancer. Int. J. Mol. Sci. Nov 2018, 19, 3890; doi:10.3390/ijms19123890.

Wu W, Karelia D, Pramanik K, Amin SG, Sharma AK, Jiang C, Lu J, Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53-mediated apoptosis in LNCaP prostate cancer cells. Mol Carcinog. 2018 Aug;57(8):1055-1066

Yong Zhang, Yinhui Dong, Michael W. Melkus, Shutao Yin, Su-Ni Tang, Peixin Jiang, Kartick Pramanik, Wei Wu, Sangyub Kim, Min Ye, Hongbo Hu, Junxuan Lu and Cheng Jiang. Role of P53-Senescence Induction in Suppression of LNCaP Prostate Cancer Growth by Cardiotonic Compound Bufalin Mol Cancer Ther. 2018 Nov;17(11):2341-2352. doi: 10.1158/1535-7163.MCT-17-1296.

Kartick C. Pramanik, Neel M. Fofaria, Parul Gupta, Alok Ranjan, Sung-Hoon Kim, Sanjay K. Srivastava. Inhibition of β-Catenin signaling suppresses pancreatic tumor growth by disrupting nuclear β-Catenin/TCF-1 complex: Critical role of STAT-3, Oncotarget, 2015, 6(13): 11561–11574

Pramanik KC, Fofaria NM, Gupta P, Srivastava SK. CBP mediated FOXO-1 acetylation inhibits pancreatic tumors growth by targeting SirT-1. Molecular Cancer Therapeutics (MCT) 2014, 13(3):687-98.

Certified by WBPC as a Registered Pharmacist

Development of natural, synthetic or biological compounds as chemo-preventive/therapeutic agent against pancreatic and lung cancer
The role of oxidant and anti-oxidant in cancer progression, chemo-resistance and metastasis